Katell Le Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katell Le Du has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Cédric Rossi
Department of Hematology, Centre Hospitalier Universitaire de Dijon, Dijon, France
4 shared publications - Frédéric Maloisel
Clinique Sainte Anne, Strasbourg, France
4 shared publications Hervé Tilly
Department of Hematology, Centre Henri Becquerel, Rouen, France
4 shared publicationsAlexandra Traverse-Glehen
27Department of Pathology, Hospices Civils de Lyon, Pierre-Bénite, France
3 shared publications- Anne-Lise Septans
Department of Biostatistics, Institut inter-régional de cancérologie, Le Mans, France
3 shared publications - David Tonnelet
Service de Médecine Nucléaire, Centre Henri Becquerel, Rouen, France
3 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Impact of electronic monitoring of adverse events in patients receiving R-CHOP therapy for diffuse large B-cell lymphoma: open-label prospective randomized controlled phase 3 trial (EMILY) (Preprint)
BACKGROUND Progression is the leading cause of death among patients receiving first line treatment for diffuse large B-cell lymphoma. Some patients die from treatment-related toxicity, secondary cancers, or comorbidities, particularly cardiovascular conditions. The early detection of these events could improve quality of life and event-free survival. OBJECTIVE This study aims to describe the adverse events that have occurred and the methods used to manage them, comparing an electronic application-assisted physician approach with standard follow-up procedures. METHODS An open-label prospective, randomized, controlled phase 3 trial was conducted to compare the impact of a web-based application for monitoring events occurring during rituximab combined with cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (R-CHOP) treatment (experimental group) with that of standard monitoring (control group). RESULTS A total of 62 patients were included in the study, with a median age of 62.0 years (Q1–Q3: 50.0–74.0). Thirty-one patients were randomized to each group (1:1 randomization). The study was terminated prematurely on October 17, 2024, due to bankruptcy of the unit responsible for promoting clinical trials. The median follow-up was 8.3 months (Q1–Q3: 1–24.2 months). In total, 617 events were reported (403 in the experimental group and 214 in the control group) (P<.01). About 340 events, including 238 in the experimental group and 102 in the control group, required intervention (P<.01). The median numbers of events per patient were 14 in the experimental group (Q1–Q3: 4–24), and 7 in the control group (Q1–Q3: 3–10) (P=.05). The mean times to treatment were 7.7 days in the overall population, 4.5 days in the experimental group, and 15.6 days in the control group (P=.14). Thirty-one events, including 13 in the experimental group and 18 in the control group, required hospitalization (P<.01). The event-free survival rates at the 12-months follow-up were 61.1% in the experimental group and 68.7% in the control group (P=.40). CONCLUSIONS Event monitoring via a web application was feasible in patients with diffuse large B-cell lymphoma, with a higher number of reports in the experimental group. Compared with the control group, the experimental group had a lower proportion of events requiring hospitalization. However, considering the premature termination and the descriptive nature of the study, these results should be interpreted as exploratory CLINICALTRIAL ClinicalTrials.gov NCT05298293
- 22 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImpact of electronic monitoring of adverse events in patients receiving R-CHOP therapy for diffuse large B-cell lymphoma: open-label prospective randomized controlled phase 3 trial (EMILY) (Preprint)
BACKGROUND Progression is the leading cause of death among patients receiving first line treatment for diffuse large B-cell lymphoma. Some patients die from treatment-related toxicity, secondary cancers, or comorbidities, particularly cardiovascular conditions. The early detection of these events could improve quality of life and event-free survival. OBJECTIVE This study aims to describe the adverse events that have occurred and the methods used to manage them, comparing an electronic application-assisted physician approach with standard follow-up procedures. METHODS An open-label prospective, randomized, controlled phase 3 trial was conducted to compare the impact of a web-based application for monitoring events occurring during rituximab combined with cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (R-CHOP) treatment (experimental group) with that of standard monitoring (control group). RESULTS A total of 62 patients were included in the study, with a median age of 62.0 years (Q1–Q3: 50.0–74.0). Thirty-one patients were randomized to each group (1:1 randomization). The study was terminated prematurely on October 17, 2024, due to bankruptcy of the unit responsible for promoting clinical trials. The median follow-up was 8.3 months (Q1–Q3: 1–24.2 months). In total, 617 events were reported (403 in the experimental group and 214 in the control group) (P<.01). About 340 events, including 238 in the experimental group and 102 in the control group, required intervention (P<.01). The median numbers of events per patient were 14 in the experimental group (Q1–Q3: 4–24), and 7 in the control group (Q1–Q3: 3–10) (P=.05). The mean times to treatment were 7.7 days in the overall population, 4.5 days in the experimental group, and 15.6 days in the control group (P=.14). Thirty-one events, including 13 in the experimental group and 18 in the control group, required hospitalization (P<.01). The event-free survival rates at the 12-months follow-up were 61.1% in the experimental group and 68.7% in the control group (P=.40). CONCLUSIONS Event monitoring via a web application was feasible in patients with diffuse large B-cell lymphoma, with a higher number of reports in the experimental group. Compared with the control group, the experimental group had a lower proportion of events requiring hospitalization. However, considering the premature termination and the descriptive nature of the study, these results should be interpreted as exploratory CLINICALTRIAL ClinicalTrials.gov NCT05298293
- Open Access
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4455-4467
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study
Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 cycles. ctDNA and tumor biopsy were analyzed by high-depth, error-corrected sequencing (limit of detection ∼10−3). Associations between MRD, PET response, and progression-free survival (PFS) were evaluated. Among 84 patients, baseline ctDNA was detected in 98%. After 4 cycles of treatment with R-CHOP14 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered every 14 days) or R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone), 87.7% had undetectable MRD. Persistence of minimal residual disease after 4 cycles of therapy (MRD4) was associated with shorter PFS (hazard ratio [HR], 78.1; 95% confidence interval [CI], 9.5-641.8). The 1-year PFS was 98.4% (95% CI, 95.4%-100%) for patients with undetectable MRD4 vs 33.3% (95% CI, 13.2%-84.0%) for patients with detectable MRD4 (P < 10^-4). MRD4 showed a higher positive predictive value (89% vs 50%) for disease progression than PET4, (PET after 4 cycles of chemotherapy) maintaining a similar negative predictive value (100% vs 93%). In multivariate analysis, only PET4−/MRD4− remained associated with PFS (adjusted HR, 0.07; 95% CI, 0.01-0.90). Plasma ctDNA represents a highly abundant source of genetic markers for tumor fingerprinting and disease monitoring. MRD detection after frontline therapy strongly complements PET response criteria in predicting outcome. These findings support the use of ctDNA monitoring as a valuable tool for future risk-adapted strategies in PMBL. This trial was registered at www.clinicaltrials.gov as NCT04980222.
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4455-4467
Open AccessInterim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study
Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 cycles. ctDNA and tumor biopsy were analyzed by high-depth, error-corrected sequencing (limit of detection ∼10−3). Associations between MRD, PET response, and progression-free survival (PFS) were evaluated. Among 84 patients, baseline ctDNA was detected in 98%. After 4 cycles of treatment with R-CHOP14 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered every 14 days) or R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone), 87.7% had undetectable MRD. Persistence of minimal residual disease after 4 cycles of therapy (MRD4) was associated with shorter PFS (hazard ratio [HR], 78.1; 95% confidence interval [CI], 9.5-641.8). The 1-year PFS was 98.4% (95% CI, 95.4%-100%) for patients with undetectable MRD4 vs 33.3% (95% CI, 13.2%-84.0%) for patients with detectable MRD4 (P < 10^-4). MRD4 showed a higher positive predictive value (89% vs 50%) for disease progression than PET4, (PET after 4 cycles of chemotherapy) maintaining a similar negative predictive value (100% vs 93%). In multivariate analysis, only PET4−/MRD4− remained associated with PFS (adjusted HR, 0.07; 95% CI, 0.01-0.90). Plasma ctDNA represents a highly abundant source of genetic markers for tumor fingerprinting and disease monitoring. MRD detection after frontline therapy strongly complements PET response criteria in predicting outcome. These findings support the use of ctDNA monitoring as a valuable tool for future risk-adapted strategies in PMBL. This trial was registered at www.clinicaltrials.gov as NCT04980222.
- Open Access
- 12 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 4898-4906
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma
Primary mediastinal B-cell lymphoma (PMBL) is an uncommon aggressive lymphoma with generally favorable outcomes; however, 15-20% of patients develop refractory disease. Reliable baseline prognostic biomarkers remain lacking. We evaluated the prognostic value of radiomic parameters derived from baseline 18F-FDG PET/CT in newly diagnosed PMBL. This post-hoc analysis included 180 treatment-naïve patients from the multicenter LYSA cohort (2007-2017) treated with rituximab plus ACVBP, R-CHOP14, or R-CHOP21. Twelve 3D PET-derived radiomic features were extracted using Oncometer3D. Inter-parameter correlations were assessed using Spearman coefficients. Receiver operating characteristic (ROC) analyses determined optimal cut-offs. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier estimates and Cox regression models. Four clusters of correlated features were identified: activity, tumor burden, massiveness/fragmentation, and dispersion. Among these, total metabolic tumor volume (TMTV), maximal inter-lesion distance (Dmax), and median peripheral centroid distance (medPCD) demonstrated the strongest prognostic associations. TMTV and Dmax were significantly associated with shorter PFS and OS, while medPCD predicted OS. In multivariable analysis adjusted for IPI, bulky disease, B symptoms, and treatment regimen, a composite radiomic score (2-3 high-risk features vs 0-1) independently predicted OS (HR 7.76, 95% CI 1.59-37.74) and showed a strong trend for PFS. The composite score outperformed conventional clinical risk factors. Baseline PET-derived radiomic features capturing tumor burden, spatial dispersion, and compactness provide independent prognostic information in PMBL. A three-parameter radiomic score outperformed conventional risk factors and identified a high-risk subgroup at diagnosis, warranting prospective and external validation before clinical implementation.
- 12 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 4898-4906
Open AccessPrognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma
Primary mediastinal B-cell lymphoma (PMBL) is an uncommon aggressive lymphoma with generally favorable outcomes; however, 15-20% of patients develop refractory disease. Reliable baseline prognostic biomarkers remain lacking. We evaluated the prognostic value of radiomic parameters derived from baseline 18F-FDG PET/CT in newly diagnosed PMBL. This post-hoc analysis included 180 treatment-naïve patients from the multicenter LYSA cohort (2007-2017) treated with rituximab plus ACVBP, R-CHOP14, or R-CHOP21. Twelve 3D PET-derived radiomic features were extracted using Oncometer3D. Inter-parameter correlations were assessed using Spearman coefficients. Receiver operating characteristic (ROC) analyses determined optimal cut-offs. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier estimates and Cox regression models. Four clusters of correlated features were identified: activity, tumor burden, massiveness/fragmentation, and dispersion. Among these, total metabolic tumor volume (TMTV), maximal inter-lesion distance (Dmax), and median peripheral centroid distance (medPCD) demonstrated the strongest prognostic associations. TMTV and Dmax were significantly associated with shorter PFS and OS, while medPCD predicted OS. In multivariable analysis adjusted for IPI, bulky disease, B symptoms, and treatment regimen, a composite radiomic score (2-3 high-risk features vs 0-1) independently predicted OS (HR 7.76, 95% CI 1.59-37.74) and showed a strong trend for PFS. The composite score outperformed conventional clinical risk factors. Baseline PET-derived radiomic features capturing tumor burden, spatial dispersion, and compactness provide independent prognostic information in PMBL. A three-parameter radiomic score outperformed conventional risk factors and identified a high-risk subgroup at diagnosis, warranting prospective and external validation before clinical implementation.
- Open Access
- 26 September 2025
- Published by Taylor & Francis in CNS Oncology
- Vol. 14 (1) , 2563981
Multiple brain lesions in a patient with relapsed hairy cell leukemia: a case report and review of the literature
Cerebral lesions are rare in hairy cell leukemia (HCL), and its incidence remains to be determined. Identifying the cause can be challenging. In this report, we present a case of brain lesions occurring several years after diagnosis. A 76-year-old male patient presented to the Emergency Department with confusion. He had been diagnosed with HCL in 1999 and had received five lines of treatment. Cerebral imaging revealed multiple nodular lesions, with edema and a hemorrhagic appearance. Cerebrospinal fluid tests were negative. The tumor origin was retained due to concomitant relapse (blood, lymph nodes). Despite the partial efficacy of rituximab-cladribine treatment, the patient died of Candida pneumonia. A review of the literature (PubMed, CrossRef, Google Scholar) identified seventeen cases between 1966 and 2024, with a median age of 59 years (33-80). Cladribine, with or without rituximab, was the most widely prescribed treatment regimen with a complete response rate of 57%. Four (23.5%) patients died (two from infection, one from gastrointestinal bleeding and one from an unknown cause). These atypical presentations suggest that brain imaging and advanced biological investigations should be performed to guide management.
- 26 September 2025
- Published by Taylor & Francis in CNS Oncology
- Vol. 14 (1) , 2563981
Open AccessMultiple brain lesions in a patient with relapsed hairy cell leukemia: a case report and review of the literature
Cerebral lesions are rare in hairy cell leukemia (HCL), and its incidence remains to be determined. Identifying the cause can be challenging. In this report, we present a case of brain lesions occurring several years after diagnosis. A 76-year-old male patient presented to the Emergency Department with confusion. He had been diagnosed with HCL in 1999 and had received five lines of treatment. Cerebral imaging revealed multiple nodular lesions, with edema and a hemorrhagic appearance. Cerebrospinal fluid tests were negative. The tumor origin was retained due to concomitant relapse (blood, lymph nodes). Despite the partial efficacy of rituximab-cladribine treatment, the patient died of Candida pneumonia. A review of the literature (PubMed, CrossRef, Google Scholar) identified seventeen cases between 1966 and 2024, with a median age of 59 years (33-80). Cladribine, with or without rituximab, was the most widely prescribed treatment regimen with a complete response rate of 57%. Four (23.5%) patients died (two from infection, one from gastrointestinal bleeding and one from an unknown cause). These atypical presentations suggest that brain imaging and advanced biological investigations should be performed to guide management.
- Open Access
- 6 May 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11 (1) , e65960
Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)
Background: Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with lung cancer; however, evidence is lacking in patients with lymphoma. We evaluated the effect of a web-mediated follow-up application for patients with lymphoma at high risk of relapse. Objective: This study aims to demonstrate that monitoring patients via a web application enables the detection of at least 30% more significant events occurring between 2 systematic follow-up consultations with the specialist using an electronic questionnaire. Methods: We conducted a prospective, randomized phase 3 trial comparing the impact of web-based follow-up (experimental arm) with a standard follow-up (control arm). The trial was based on a 2-step triangular test and was designed to have a power of 90% to detect a 30% improvement in the detection of significant events. A significant event was defined as a relapse, progression, or a serious adverse event. The study covered the follow-up period after completion of first-line treatment or relapse (24 months). Eligible patients were aged 18 years and older and had lymphoma at a high risk of relapse. In the experimental arm, patients received a 16-symptom questionnaire by email every 2 weeks. An email alert was sent to the medical team based on a predefined algorithm. The primary objective was assessed after the inclusion of the 40th patient. The study was continued for the duration of the analysis. Results: A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France, with 27 in the experimental arm and 25 in the control arm. The median follow-up was 21.3 (range 1.3‐25.6) months, and 121 events were reported during the study period. Most events occurred in the experimental arm (83/119, 69.7%) compared with 30.2% (36/119) in the control arm. A median number of 3.5 (range 1-8) events per patient occurred in the experimental arm, and 1.8 (range 1-6) occurred in the control arm (P=.01). Progression and infection were the most frequently reported events. Further, 19 patients relapsed during follow-up: 6 in the experimental arm and 13 in the control arm (P<.001), with a median follow-up of 7.7 (range 2.8‐20.6) months and 6.7 (range 1.9‐16.4) months (P=.94), respectively. Statistical analysis was conducted after including the 40th patient, which showed no superiority of the experimental arm over the control arm. The study was therefore stopped after the 52nd patient was enrolled. Conclusions: The primary objective was not reached; however, patient-reported outcome measures remain essential for detecting adverse events in patients with cancer, and the electronic monitoring method needs to demonstrate its effectiveness and comply with international safety guidelines.
- 6 May 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11 (1) , e65960
Open AccessComparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)
Background: Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with lung cancer; however, evidence is lacking in patients with lymphoma. We evaluated the effect of a web-mediated follow-up application for patients with lymphoma at high risk of relapse. Objective: This study aims to demonstrate that monitoring patients via a web application enables the detection of at least 30% more significant events occurring between 2 systematic follow-up consultations with the specialist using an electronic questionnaire. Methods: We conducted a prospective, randomized phase 3 trial comparing the impact of web-based follow-up (experimental arm) with a standard follow-up (control arm). The trial was based on a 2-step triangular test and was designed to have a power of 90% to detect a 30% improvement in the detection of significant events. A significant event was defined as a relapse, progression, or a serious adverse event. The study covered the follow-up period after completion of first-line treatment or relapse (24 months). Eligible patients were aged 18 years and older and had lymphoma at a high risk of relapse. In the experimental arm, patients received a 16-symptom questionnaire by email every 2 weeks. An email alert was sent to the medical team based on a predefined algorithm. The primary objective was assessed after the inclusion of the 40th patient. The study was continued for the duration of the analysis. Results: A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France, with 27 in the experimental arm and 25 in the control arm. The median follow-up was 21.3 (range 1.3‐25.6) months, and 121 events were reported during the study period. Most events occurred in the experimental arm (83/119, 69.7%) compared with 30.2% (36/119) in the control arm. A median number of 3.5 (range 1-8) events per patient occurred in the experimental arm, and 1.8 (range 1-6) occurred in the control arm (P=.01). Progression and infection were the most frequently reported events. Further, 19 patients relapsed during follow-up: 6 in the experimental arm and 13 in the control arm (P<.001), with a median follow-up of 7.7 (range 2.8‐20.6) months and 6.7 (range 1.9‐16.4) months (P=.94), respectively. Statistical analysis was conducted after including the 40th patient, which showed no superiority of the experimental arm over the control arm. The study was therefore stopped after the 52nd patient was enrolled. Conclusions: The primary objective was not reached; however, patient-reported outcome measures remain essential for detecting adverse events in patients with cancer, and the electronic monitoring method needs to demonstrate its effectiveness and comply with international safety guidelines.
- Open Access
- 31 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Randomized trial comparing a web-based follow-up with routine surveillance in high-risk lymphoma: results of the phase 3 Sentinel Lymphoma trial. (Preprint)
BACKGROUND Relapse is a major event for lymphoma patients. Early detection could have an impact on quality of life and overall survival. Patient-related outcome measures have already demonstrated clinical benefit for lung cancer patients. Evidence is lacking for lymphoma patients. We proposed to evaluate the impact of a web-application follow-up for lymphoma patients at high risk of relapse. OBJECTIVE The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. METHODS We planned a prospective, randomized phase 3 trial, comparing web-based follow-up (experimental arm) to a standard arm (control arm). Eligible patients were 18 years of age and older with lymphoma at high risk of relapse. Patients could have T-cell lymphoma in first partial or complete response, Hodgkin lymphoma in second partial or complete response, or diffuse large B-cell lymphoma in first partial or complete response with a revised high IPI score (≥3) or in second partial or complete response. The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. An interim analysis was performed at the inclusion of the first 40 patients. RESULTS A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France: 27 in the experimental arm and 25 in the control arm. Median follow-up was 21.3 months (range, [1.3-25.6] months). One hundred and twenty-one events were reported during the study period. Most events were reported in the experimental arm (83/119, 69.7%) compared to 30.2% (36/119) in the control arm, with a mean number of events per patient of 3.5 in the experimental arm and 1.8 in the control arm (p=.0041). Progression and infection were most frequently reported events. Nineteen patients relapsed during follow-up: 6 in the experimental arm and 13 in the standard arm (p<.001), with a median follow-up of 7.7 (range, [2.8-20.6] months) and 6.7 (range [1.9-16.4] months) (p=.94) respectively. Nine out of 26 patients (34.6%) in the experimental group did not receive their electronic questionnaire and the supplier was unable to remedy this. The interim analysis showed that there was no difference in the diagnosis of events. CONCLUSIONS PRO measures remain essential, but the electronic monitoring method must comply with international safety guidelines. CLINICALTRIAL ClinicalTrials.gov NCT 03154710
- 31 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessRandomized trial comparing a web-based follow-up with routine surveillance in high-risk lymphoma: results of the phase 3 Sentinel Lymphoma trial. (Preprint)
BACKGROUND Relapse is a major event for lymphoma patients. Early detection could have an impact on quality of life and overall survival. Patient-related outcome measures have already demonstrated clinical benefit for lung cancer patients. Evidence is lacking for lymphoma patients. We proposed to evaluate the impact of a web-application follow-up for lymphoma patients at high risk of relapse. OBJECTIVE The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. METHODS We planned a prospective, randomized phase 3 trial, comparing web-based follow-up (experimental arm) to a standard arm (control arm). Eligible patients were 18 years of age and older with lymphoma at high risk of relapse. Patients could have T-cell lymphoma in first partial or complete response, Hodgkin lymphoma in second partial or complete response, or diffuse large B-cell lymphoma in first partial or complete response with a revised high IPI score (≥3) or in second partial or complete response. The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. An interim analysis was performed at the inclusion of the first 40 patients. RESULTS A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France: 27 in the experimental arm and 25 in the control arm. Median follow-up was 21.3 months (range, [1.3-25.6] months). One hundred and twenty-one events were reported during the study period. Most events were reported in the experimental arm (83/119, 69.7%) compared to 30.2% (36/119) in the control arm, with a mean number of events per patient of 3.5 in the experimental arm and 1.8 in the control arm (p=.0041). Progression and infection were most frequently reported events. Nineteen patients relapsed during follow-up: 6 in the experimental arm and 13 in the standard arm (p<.001), with a median follow-up of 7.7 (range, [2.8-20.6] months) and 6.7 (range [1.9-16.4] months) (p=.94) respectively. Nine out of 26 patients (34.6%) in the experimental group did not receive their electronic questionnaire and the supplier was unable to remedy this. The interim analysis showed that there was no difference in the diagnosis of events. CONCLUSIONS PRO measures remain essential, but the electronic monitoring method must comply with international safety guidelines. CLINICALTRIAL ClinicalTrials.gov NCT 03154710
- Top Cited PapersOpen Access
- 31 July 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 44, 101005
Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium
- 31 July 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 44, 101005
Top Cited PapersOpen AccessImplementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium
- Open Access
- 15 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e38619
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study
Background: Evidence regarding the analgesic effect of distraction through immersion in virtual reality (VR) for care-induced pain has been documented in several phase 2 trials, but comparison with standard treatments in large, randomized studies is needed. Objective: In this open-label, multicenter, randomized, phase 3 trial, we evaluated the safety and efficacy of a novel VR therapy solution for distraction in the context of bone marrow biopsy. Methods: Bliss is a VR software with 4 imaginary interactive environments in 3 dimensions with binaural sound (head-mounted display). Efficacy regarding pain intensity was evaluated using a visual analog scale (VAS; score from 0 to 10) immediately after the biopsy. Secondary end points were anxiety and tolerance. Modified intention-to-treat analysis was performed. Results: Overall, 126 patients with previously documented untreated or suspected malignant hemopathy between September 6, 2018, and May 18, 2020, were randomly assigned in a 1:1 ratio to receive pain prevention with a mixture of nitrous oxide/oxygen (MEOPA; n=63) or VR (n=63) before and during the bone marrow biopsy. We excluded 8 patients from the final analysis (3 in the MEOPA group and 5 in the VR group). All patients received local anesthesia (lidocaine) before biopsy. Follow-up was limited to 1 month after the biopsy. Participants’ median age was 65.5 (range 18-87) years, and 54.2% (64/118) of patients were male. The average pain intensity was 3.5 (SD 2.6, 95% CI –1.6 to 8.6) for the MEOPA group and 3.0 (SD 2.4, 95% CI –1.7 to 7.7) for the VR group, without any significant differences in age, sex, center, and hemopathy (P=.26). Concerning anxiety, 67.5% (79/117; fear of pain questionnaire) of the patients were afraid before the biopsy, and anxiety scores were moderate to very high in 26.3% (30/114; revised Spielberger State-Trait Anxiety Inventory questionnaire) of the patients before the biopsy and 9.0% (10/114) after the biopsy for all patients, without a significant difference between the 2 groups (P=.83). Immersion in VR was well tolerated by the majority (54/57, 95%) of patients in the VR group. Conclusions: The intensity of pain did not significantly differ between both arms. VR was well tolerated, and the satisfaction of patients, nurses, and physicians was very high. VR could be an alternative treatment in case of contraindication or intolerance to MEOPA. Trial Registration: ClinicalTrials.gov NCT03483194; https://clinicaltrials.gov/ct2/show/NCT03483194
- 15 February 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e38619
Open AccessA New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study
Background: Evidence regarding the analgesic effect of distraction through immersion in virtual reality (VR) for care-induced pain has been documented in several phase 2 trials, but comparison with standard treatments in large, randomized studies is needed. Objective: In this open-label, multicenter, randomized, phase 3 trial, we evaluated the safety and efficacy of a novel VR therapy solution for distraction in the context of bone marrow biopsy. Methods: Bliss is a VR software with 4 imaginary interactive environments in 3 dimensions with binaural sound (head-mounted display). Efficacy regarding pain intensity was evaluated using a visual analog scale (VAS; score from 0 to 10) immediately after the biopsy. Secondary end points were anxiety and tolerance. Modified intention-to-treat analysis was performed. Results: Overall, 126 patients with previously documented untreated or suspected malignant hemopathy between September 6, 2018, and May 18, 2020, were randomly assigned in a 1:1 ratio to receive pain prevention with a mixture of nitrous oxide/oxygen (MEOPA; n=63) or VR (n=63) before and during the bone marrow biopsy. We excluded 8 patients from the final analysis (3 in the MEOPA group and 5 in the VR group). All patients received local anesthesia (lidocaine) before biopsy. Follow-up was limited to 1 month after the biopsy. Participants’ median age was 65.5 (range 18-87) years, and 54.2% (64/118) of patients were male. The average pain intensity was 3.5 (SD 2.6, 95% CI –1.6 to 8.6) for the MEOPA group and 3.0 (SD 2.4, 95% CI –1.7 to 7.7) for the VR group, without any significant differences in age, sex, center, and hemopathy (P=.26). Concerning anxiety, 67.5% (79/117; fear of pain questionnaire) of the patients were afraid before the biopsy, and anxiety scores were moderate to very high in 26.3% (30/114; revised Spielberger State-Trait Anxiety Inventory questionnaire) of the patients before the biopsy and 9.0% (10/114) after the biopsy for all patients, without a significant difference between the 2 groups (P=.83). Immersion in VR was well tolerated by the majority (54/57, 95%) of patients in the VR group. Conclusions: The intensity of pain did not significantly differ between both arms. VR was well tolerated, and the satisfaction of patients, nurses, and physicians was very high. VR could be an alternative treatment in case of contraindication or intolerance to MEOPA. Trial Registration: ClinicalTrials.gov NCT03483194; https://clinicaltrials.gov/ct2/show/NCT03483194
- Open Access
- 24 November 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (11) , e40969
Physical Activity Program for the Survival of Elderly Patients With Lymphoma: Study Protocol for Randomized Phase 3 Trial
Background: The practice of regular physical activity can reduce the incidence of certain cancers (colon, breast, and prostate) and improve overall survival after treatment by reducing fatigue and the risk of relapse. This impact on survival has only been demonstrated in active patients with lymphoma before and after treatment. As poor general health status reduces the chances of survival and these patients are most likely to also have sarcopenia, it is important to be able to improve their physical function through adapted physical activity (APA) as part of supportive care management. Unfortunately, APA is often saved for patients with advanced blood cancer. As a result, there is a lack of data regarding the impact of standardized regular practice of APA and concomitant chemotherapy as first-line treatment on lymphoma survival.Objective: This study aimed to assess the impact of a new and open rehabilitation program suitable for a frail population of patients treated for diffuse large B-cell lymphoma (DLBCL).Methods: PHARAOM (Physical Activity Program for the Survival of Elderly Patients with Lymphoma) is a phase 3 randomized (1:1) study focusing on a frail population of patients treated for DLBCL. The study will include 186 older adult patients with DLBCL (aged >65 years) receiving rituximab and chemotherapy. Overall, 50% (93/186) of patients (investigational group) will receive APA along with chemotherapy, and they will be supervised by a dedicated qualified kinesiologist. The APA program will include endurance and resistance training at moderate intensity 3 times a week during the 6 months of chemotherapy. The primary end point of this study will be event-free survival of the patients. The secondary end points will include the overall survival, progression-free survival, prevalence of sarcopenia and undernutrition, and patients' quality of life. This study will be conducted in accordance with the principles of the Declaration of Helsinki.Results: Recruitment, enrollment, and data collection began in February 2021, and 4 participants have been enrolled in the study as of July 2022. Data analysis will begin after the completion of data collection. Future outcomes will be published in peer-reviewed health-related research journals and presented at national congress, and state professional meetings. This publication is based on protocol version 1.1, August 3, 2020.Conclusions: The PHARAOM study focuses on highlighting the benefits of APA intervention on survival during the period of first-line treatment of patients with DLBCL. This study could also contribute to our understanding of how an APA program can reduce complications such as sarcopenia in patients with lymphoma and improve their quality of life. By documenting the prevalence and relationship between sarcopenia and exercise load, we might be able to help physicians plan better interventions in the care of patients with DLBCL.Trial Registration: ClinicalTrials.gov NCT04670029; https://clinicaltrials.gov/ct2/show/NCT04670029International Registered Report Identifier (IRRID): DERR1-10.2196/40969
- 24 November 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (11) , e40969
Open AccessPhysical Activity Program for the Survival of Elderly Patients With Lymphoma: Study Protocol for Randomized Phase 3 Trial
Background: The practice of regular physical activity can reduce the incidence of certain cancers (colon, breast, and prostate) and improve overall survival after treatment by reducing fatigue and the risk of relapse. This impact on survival has only been demonstrated in active patients with lymphoma before and after treatment. As poor general health status reduces the chances of survival and these patients are most likely to also have sarcopenia, it is important to be able to improve their physical function through adapted physical activity (APA) as part of supportive care management. Unfortunately, APA is often saved for patients with advanced blood cancer. As a result, there is a lack of data regarding the impact of standardized regular practice of APA and concomitant chemotherapy as first-line treatment on lymphoma survival.Objective: This study aimed to assess the impact of a new and open rehabilitation program suitable for a frail population of patients treated for diffuse large B-cell lymphoma (DLBCL).Methods: PHARAOM (Physical Activity Program for the Survival of Elderly Patients with Lymphoma) is a phase 3 randomized (1:1) study focusing on a frail population of patients treated for DLBCL. The study will include 186 older adult patients with DLBCL (aged >65 years) receiving rituximab and chemotherapy. Overall, 50% (93/186) of patients (investigational group) will receive APA along with chemotherapy, and they will be supervised by a dedicated qualified kinesiologist. The APA program will include endurance and resistance training at moderate intensity 3 times a week during the 6 months of chemotherapy. The primary end point of this study will be event-free survival of the patients. The secondary end points will include the overall survival, progression-free survival, prevalence of sarcopenia and undernutrition, and patients' quality of life. This study will be conducted in accordance with the principles of the Declaration of Helsinki.Results: Recruitment, enrollment, and data collection began in February 2021, and 4 participants have been enrolled in the study as of July 2022. Data analysis will begin after the completion of data collection. Future outcomes will be published in peer-reviewed health-related research journals and presented at national congress, and state professional meetings. This publication is based on protocol version 1.1, August 3, 2020.Conclusions: The PHARAOM study focuses on highlighting the benefits of APA intervention on survival during the period of first-line treatment of patients with DLBCL. This study could also contribute to our understanding of how an APA program can reduce complications such as sarcopenia in patients with lymphoma and improve their quality of life. By documenting the prevalence and relationship between sarcopenia and exercise load, we might be able to help physicians plan better interventions in the care of patients with DLBCL.Trial Registration: ClinicalTrials.gov NCT04670029; https://clinicaltrials.gov/ct2/show/NCT04670029International Registered Report Identifier (IRRID): DERR1-10.2196/40969
- Open Access
- 11 July 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Physical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint)
BACKGROUND Older adults suffering from cancer receive a treatment that, in most cases, causes symptoms such as fatigue, weakness, sleep disturbances, and lethargy. Moreover, the toxicity of the chemotherapy itself can also affect the physical function and the quality of life of cancer patients. Since a poor general health status reduces the chances of survival and these patients are most likely to also suffer from sarcopenia, it is therefore important to be able to improve their physical function through adapted physical activity (APA) as part of a supportive care management. Unfortunately, APA is too often saved for patients in an advanced stage of blood cancer. As a result, there is a lack of data regarding the impact of a regular practice of physical activity (that is concomitant to the administration of chemotherapy) on cancer survival. OBJECTIVE The aim of this study is to assess a new and open rehabilitation program suitable for a frail population of patients that are treated for diffuse large B-cell lymphoma (DLBCL). METHODS PHARAOM (Physical Activity program for the survival of elderly patients with lymphoma) is a phase 3 (1:1) randomized study focusing on a frail population of patients treated for DLBCL. It will include a total of 186 elderly DLBCL patients (aged over 65 years) receiving rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP); of these, 93 patients (the investigational group) will receive APA that will be supervised by a dedicated qualified kinesiologist, in addition to chemotherapy. The primary endpoint of this study will be the patients’ event-free survival. Secondary endpoints will include the overall survival, the progression-free survival, the prevalence rates of sarcopenia and undernutrition, as well as the patients’ quality of life. RESULTS The study has been approved by the internal Ethical Committee, and was registered as a clinical trial (NCT04670029) on December 16, 2020. The study will be undertaken in accordance with the Declaration of Helsinki. CONCLUSIONS This study will highlight the benefits of regular APA on the survival of patients treated for a DLBCL. This study could also contribute to our understanding of how an adapted physical program can reduce sarcopenia in cancer patients, and improve their quality of life. By documenting the prevalence and the relationship between sarcopenia and exercise load, we might be able to help physicians to plan better interventions in DLBCL patients. CLINICALTRIAL Clinical Trial: NCT04670029
- 11 July 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPhysical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint)
BACKGROUND Older adults suffering from cancer receive a treatment that, in most cases, causes symptoms such as fatigue, weakness, sleep disturbances, and lethargy. Moreover, the toxicity of the chemotherapy itself can also affect the physical function and the quality of life of cancer patients. Since a poor general health status reduces the chances of survival and these patients are most likely to also suffer from sarcopenia, it is therefore important to be able to improve their physical function through adapted physical activity (APA) as part of a supportive care management. Unfortunately, APA is too often saved for patients in an advanced stage of blood cancer. As a result, there is a lack of data regarding the impact of a regular practice of physical activity (that is concomitant to the administration of chemotherapy) on cancer survival. OBJECTIVE The aim of this study is to assess a new and open rehabilitation program suitable for a frail population of patients that are treated for diffuse large B-cell lymphoma (DLBCL). METHODS PHARAOM (Physical Activity program for the survival of elderly patients with lymphoma) is a phase 3 (1:1) randomized study focusing on a frail population of patients treated for DLBCL. It will include a total of 186 elderly DLBCL patients (aged over 65 years) receiving rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP); of these, 93 patients (the investigational group) will receive APA that will be supervised by a dedicated qualified kinesiologist, in addition to chemotherapy. The primary endpoint of this study will be the patients’ event-free survival. Secondary endpoints will include the overall survival, the progression-free survival, the prevalence rates of sarcopenia and undernutrition, as well as the patients’ quality of life. RESULTS The study has been approved by the internal Ethical Committee, and was registered as a clinical trial (NCT04670029) on December 16, 2020. The study will be undertaken in accordance with the Declaration of Helsinki. CONCLUSIONS This study will highlight the benefits of regular APA on the survival of patients treated for a DLBCL. This study could also contribute to our understanding of how an adapted physical program can reduce sarcopenia in cancer patients, and improve their quality of life. By documenting the prevalence and the relationship between sarcopenia and exercise load, we might be able to help physicians to plan better interventions in DLBCL patients. CLINICALTRIAL Clinical Trial: NCT04670029